TAKEDA PHARMACEUTICAL CO LTD's ticker is TAK and the CUSIP is 874060205. A total of 10 filers reported holding TAKEDA PHARMACEUTICAL CO LTD in Q3 2013. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $20,231,000 | -8.8% | 1,111,580 | -10.6% | 0.06% | -20.0% |
| Q3 2020 | $22,189,000 | +20.1% | 1,243,782 | +20.7% | 0.08% | +10.3% |
| Q2 2020 | $18,476,000 | +62.2% | 1,030,442 | +37.3% | 0.07% | +36.0% |
| Q1 2020 | $11,393,000 | -43.1% | 750,544 | -26.1% | 0.05% | -30.6% |
| Q4 2019 | $20,031,000 | +40.8% | 1,015,231 | +22.7% | 0.07% | +28.6% |
| Q3 2019 | $14,229,000 | +34.4% | 827,273 | +38.3% | 0.06% | +30.2% |
| Q2 2019 | $10,584,000 | -41.1% | 597,964 | -32.2% | 0.04% | -44.9% |
| Q1 2019 | $17,975,000 | +346.8% | 882,411 | +268.9% | 0.08% | +290.0% |
| Q4 2018 | $4,023,000 | -41.7% | 239,187 | -17.6% | 0.02% | -79.4% |
| Q1 2014 | $6,895,000 | +6.6% | 290,284 | +3.0% | 0.10% | -3.0% |
| Q4 2013 | $6,470,000 | +16.6% | 281,882 | +19.9% | 0.10% | -6.5% |
| Q3 2013 | $5,551,000 | +20.3% | 235,055 | +14.8% | 0.11% | -2.7% |
| Q2 2013 | $4,615,000 | – | 204,669 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Adelphi Capital LLP | 9,270,535 | $188,841,000 | 39.13% |
| Sachem Head Capital | 5,963,600 | $121,479,000 | 7.38% |
| NINE MASTS CAPITAL Ltd | 1,049,886 | $21,415,000 | 6.68% |
| Paulson & Co. | 26,489,422 | $539,590,000 | 5.77% |
| Blackcrane Capital, LLC | 189,549 | $3,861,000 | 5.16% |
| Glenview Capital Management | 26,112,660 | $531,915,000 | 4.75% |
| Exane Asset Management | 430,369 | $8,766,617,000 | 4.26% |
| Velanne Asset Management Ltd | 281,972 | $5,744,000 | 3.97% |
| Bluefin Trading, LLC | 1,204,702 | $24,540,000 | 3.55% |
| Endurant Capital Management LP | 437,436 | $8,911,000 | 3.52% |